Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes

Didas, Nutsiwat; Thitisopee, Witsawat; Porntadavity, Sureerut; Jeenduang, Nutjaree

doi:10.1007/s11255-020-02547-2

Cited by 4 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study is the first report of the association of the PON1 L55M and Q192R polymorphisms and CKD in T2DM, as well as their relationship to PON1 activity in Thai individuals. The study extended our previous work that demonstrated that low AREase activity increased the risk of CKD in T2DM 15 . The AREase activity, but not the PONase activity, was significantly lower in CKD patients than in non‐CKD patients in this study.…”

Section: Discussionsupporting

confidence: 87%

“…The study extended our previous work that demonstrated that low AREase activity increased the risk of CKD in T2DM. 15 The AREase activity, but not the PONase activity, was significantly lower in CKD patients than in non-CKD patients in this study. A previous study showed that AREase activity was a more sensitive and specific predictor of CKD than PONase activity.…”

Section: Discussioncontrasting

confidence: 55%

“…Moreover, a previous study showed that lower AREase activity increased the risk for CKD in T2DM. 15 This suggests that T2DM patients who are RR carriers with lower AREase activity may be predisposed to the development of CKD.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies showed that PON1 activity was decreased in patients with acute coronary syndrome (ACS), 12,13 CKD 5 and end‐stage renal disease (ESRD) 14 . In addition, decreased PON1 activity was associated with an increased risk for CKD 5,15 . Although the association between the PON1 L55M and Q192R polymorphisms and CKD in the general population 16 and diabetic complications in patients with T1DM and T2DM 17,18 has been studied, studies on the association of the PON1 L55M, and Q192R polymorphisms with CKD in T2DM are rare.…”

Section: Introductionmentioning

confidence: 99%

“…14 In addition, decreased PON1 activity was associated with an increased risk for CKD. 5,15 Although the association between the PON1 L55M and Q192R polymorphisms and CKD in the general population 16 and diabetic complications in patients with T1DM and T2DM 17,18 has been studied, studies on the association of the PON1 L55M, and Q192R polymorphisms with CKD in T2DM are rare. Therefore, in this study, we aimed to investigate the association of the PON1 L55M and Q192R polymorphisms with CKD in T2DM, as well as their relationship to PON1 activity.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Paraoxonase 1 ( PON1 ) L55M and Q192R polymorphisms are not associated with chronic kidney disease in Thai individuals with type 2 diabetes

Nawaka

Pansang

Saniwa

et al. 2021

Int J Clinical Practice

Self Cite

View full text Add to dashboard Cite

Background Decreased paraoxonase 1 (PON1) activity and PON1 polymorphisms have been found to be associated with chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM). Objective This study aimed to investigate the association of the PON1 L55M and Q192R polymorphisms with CKD in T2DM, as well as their relationship with PON1 activity. Methods A total of 166 T2DM patients, including 83 CKD patients and 83 non‐CKD patients, were recruited. Biochemical parameters and paraoxonase (PONase) and arylesterase (AREase) activities were measured. The PON1 L55M and Q192R polymorphisms were analysed by a polymerase chain reaction and restriction fragment length polymorphism (PCR‐RFLP) method. Data were analysed using the chi‐square test, Student's t‐test and logistic regression analysis. Results Total cholesterol, TGs, LDL‐C and Cr were significantly higher in CKD patients than in non‐CKD patients. In contrast, the estimated glomerular filtration rate (eGFR) and AREase activity were significantly lower in CKD patients than in non‐CKD patients (P < .05). The genotype and allele frequencies of the PON1 L55M and Q192R polymorphisms were not significantly different between CKD and non‐CKD patients. Multivariate logistic regression analysis showed no association between the PON1 L55M and Q192R polymorphisms and CKD in T2DM. In addition, among all patients, patients with the PON1 LM genotype had significantly lower PONase activity than those with the LL genotype (P < .05). Among all patients, CKD patients and non‐CKD patients, those with the PON1 RR genotype had significantly higher PONase activity but lower AREase activity than patients with the QR and QQ genotypes (P < .05). Conclusions PON1 activity was influenced by the PON1 L55M and Q192R polymorphisms. However, the PON1 L55M and Q192R polymorphisms may not be considered genetic biomarkers for CKD in T2DM.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussioncontrasting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Paraoxonase 1 ( PON1 ) L55M and Q192R polymorphisms are not associated with chronic kidney disease in Thai individuals with type 2 diabetes

Nawaka

Pansang

Saniwa

et al. 2021

Int J Clinical Practice

Self Cite

View full text Add to dashboard Cite

show abstract

The importance of paraoxonase 1 activity in chronic kidney disease

Samouilidou,

Liaouri,

Kostopoulos

et al. 2024

Renal Failure

View full text Add to dashboard Cite

PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function

Kheirkhah

Lamina

Kollerits

et al. 2022

CJASN

View full text Add to dashboard Cite

Background and objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of lipid homeostasis. Studies investigating the association between PCSK9 and cardiovascular disease in large cohorts of CKD patients are limited. Design, setting, participants, and measurements: The association of PCSK9 concentrations with prevalent and incident cardiovascular disease was investigated in 5,138 Caucasians of the German Chronic Kidney Disease study with a median follow-up of 6.5 years. Inclusion criteria were eGFR of 30-60 mL/min/1.73 m2 or an eGFR>60 mL/min/1.73m2 in the presence of overt proteinuria (urine albumin-creatinine ratio >300mg/g or equivalent). Prevalent cardiovascular disease was defined as history of non-fatal myocardial infarction, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, carotid arteries interventions and stroke. Incident major adverse cardiovascular disease events included death from cardiovascular causes, acute non-fatal myocardial infarction and non-fatal stroke. Results: Median PCSK9 concentration in the cohort was 285 ng/mL (interquartile range 231-346 ng/mL). There was no association between PCSK9 concentrations and baseline eGFR and albuminuria. With each 100 ng/ml increment of PCSK9, the odds for prevalent cardiovascular disease (n=1,284) was 1.22-fold (95%CI 1.12-1.34, p<0.001) higher in a model with extended adjustment for major confounders. This association was stronger in non-statin than statin-users (p-value for interaction=0.009). During follow-up 474 individuals experienced a major adverse cardiovascular disease event and participants in PCSK9 quartiles 2 to 4 had a 32%-47% higher risk compared to quartile 1 (p<0.05). Subgroup analysis revealed this association was restricted to those participants who already had cardiovascular disease at baseline (all HR>1.75, p<0.05). In addition, PCSK9 showed a valuable gain in classification accuracy both for prevalent cardiovascular disease (NRI=0.27, 95%CI:0.20-0.33) and incident major adverse cardiovascular disease events during follow-up (NRI=0.10, 95%CI:0.008-0.21) when added to an extended adjustment model. Conclusions: Our findings reveal no relation of PCSK9 with baseline eGFR and albuminuria, but a significant association between higher PCSK9 concentrations and risk of cardiovascular disease independent of traditional risk factors including LDL-cholesterol levels.

show abstract

Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes

Cited by 4 publications

References 43 publications

Paraoxonase 1 ( PON1 ) L55M and Q192R polymorphisms are not associated with chronic kidney disease in Thai individuals with type 2 diabetes

Paraoxonase 1 ( PON1 ) L55M and Q192R polymorphisms are not associated with chronic kidney disease in Thai individuals with type 2 diabetes

The importance of paraoxonase 1 activity in chronic kidney disease

PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function

Contact Info

Product

Resources

About